Frequency of TP 53 Mutations in Relation to Arg 72 Pro Genotypes in Non – Small Cell Lung Cancer

Mutations in the TP53 gene are important events during human lung carcinogenesis. The TP53 gene harbors several polymorphisms, and functional studies have shown that the Arg72Pro polymorphism alters both wild-type and mutant p53 protein activity. Thus, we hypothesized that certain Arg72Pro genotypes may influence the frequency and pattern of somatic mutations in TP53 . We therefore examined the status of the Arg72Pro polymorphism and TP53 mutations in 260 non–small-cell lung cancer cases. Here we report a significant trend toward lower frequency of TP53 mutations with increasing number of Pro72 alleles (P = 0.02). Overall, Pro72 allele carriers had significantly lower frequency of TP53 mutations compared with Arg72 homozygotes (P = 0.02). In addition, carriage of the Pro72 variant was related to a lower frequency of mutations affecting the hotspot codon 273. Mutations at codon 273 accounted for 10.6% of the mutations in Arg72 homozygotes and 1.7% of the mutations in Pro72 allele carriers. Our results suggest that the genotype of the Arg72Pro polymorphism may modulate the frequency of TP53 mutations in non– small-cell lung cancer. (Cancer Epidemiol Biomarkers Prev 2007;16(10):2077–81)

[1]  S. Chanock,et al.  Common Genetic Variation in TP53 Is Associated with Lung Cancer Risk and Prognosis in African Americans and Somatic Mutations in Lung Tumors , 2007, Cancer Epidemiology Biomarkers & Prevention.

[2]  M. Zvelebil,et al.  iASPP preferentially binds p53 proline-rich region and modulates apoptotic function of codon 72–polymorphic p53 , 2006, Nature Genetics.

[3]  P. Brennan,et al.  Sequence variants in cell cycle control pathway, X-ray exposure, and lung cancer risk: a multicenter case-control study in Central Europe. , 2006, Cancer research.

[4]  K. Sabapathy,et al.  Trp53-dependent DNA-repair is affected by the codon 72 polymorphism , 2006, Oncogene.

[5]  Å. Borg,et al.  Increased risk of non-small cell lung cancer and frequency of somatic TP53 gene mutations in Pro72 carriers of TP53 Arg72Pro polymorphism. , 2006, Lung cancer.

[6]  M. Murphy,et al.  Polymorphisms in the p53 pathway , 2006, Oncogene.

[7]  A. Børresen-Dale,et al.  Evaluation of arrayed primer extension for TP53 mutation detection in breast and ovarian carcinomas. , 2005, BioTechniques.

[8]  C. Marsit,et al.  TP53 mutation, allelism and survival in non-small cell lung cancer. , 2005, Carcinogenesis.

[9]  K. Sabapathy,et al.  Evaluation of the Combined Effect of p53 Codon 72 Polymorphism and Hotspot Mutations in Response to Anticancer Drugs , 2005, Clinical Cancer Research.

[10]  M. Mcdermott,et al.  The p53 Codon 72 Proline Allele Is Associated with p53 Gene Mutations in Non–Small Cell Lung Cancer , 2005, Clinical Cancer Research.

[11]  J. Ferlay,et al.  Global Cancer Statistics, 2002 , 2005, CA: a cancer journal for clinicians.

[12]  C. Liao,et al.  p53 polymorphisms associated with mutations in and loss of heterozygosity of the p53 gene in male oral squamous cell carcinomas in Taiwan , 2004, British Journal of Cancer.

[13]  Leah E Mechanic,et al.  Polymorphisms in XPD and TP53 and mutation in human lung cancer. , 2004, Carcinogenesis.

[14]  R. Schneider-Stock,et al.  Selective loss of codon 72 proline p53 and frequent mutational inactivation of the retained arginine allele in colorectal cancer. , 2004, Neoplasia.

[15]  T. Crook,et al.  Polymorphism in wild-type p53 modulates response to chemotherapy in vitro and in vivo , 2004, Oncogene.

[16]  Xinbin Chen,et al.  Mutant p53 exerts a dominant negative effect by preventing wild-type p53 from binding to the promoter of its target genes , 2004, Oncogene.

[17]  D. Pim,et al.  p53 polymorphic variants at codon 72 exert different effects on cell cycle progression , 2004, International journal of cancer.

[18]  G. Gaudernack,et al.  Evaluation of denaturing conditions in analysis of DNA variants applied to multi-capillary electrophoresis instruments , 2003 .

[19]  T. Eisen,et al.  TP53 polymorphisms and lung cancer risk: a systematic review and meta-analysis. , 2003, Mutagenesis.

[20]  B. Gusterson,et al.  p53 polymorphism influences response in cancer chemotherapy via modulation of p73-dependent apoptosis. , 2003, Cancer cell.

[21]  M. Murphy,et al.  The codon 72 polymorphic variants of p53 have markedly different apoptotic potential , 2003, Nature Genetics.

[22]  P. Lønning,et al.  The TP53 codon 72 polymorphism may affect the function of TP53 mutations in breast carcinomas but not in colorectal carcinomas. , 2002, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[23]  P. Ekstrøm,et al.  Detection of mutations in exon 8 of TP53 by temperature gradient 96-capillary array electrophoresis. , 2002, BioTechniques.

[24]  C. Harris,et al.  The IARC TP53 database: New online mutation analysis and recommendations to users , 2002, Human mutation.

[25]  T. Shuin,et al.  p53 mutation arising in Arg72 allele in the tumorigenesis and development of carcinoma of the urinary tract. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.

[26]  M. Spitz,et al.  p53 Genotypes and Haplotypes Associated With Lung Cancer Susceptibility and Ethnicity. , 2002, Journal of the National Cancer Institute.

[27]  A. Inga,et al.  Tumour p53 mutations exhibit promoter selective dominance over wild type p53 , 2002, Oncogene.

[28]  R. Iggo,et al.  Inactivate the remaining p53 allele or the alternate p73? Preferential selection of the Arg72 polymorphism in cancers with recessive p53 mutants but not transdominant mutants. , 2001, Carcinogenesis.

[29]  A. Levine,et al.  Surfing the p53 network , 2000, Nature.

[30]  C. Harris,et al.  Cancer risk and low-penetrance susceptibility genes in gene-environment interactions. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[31]  B. Gusterson,et al.  A common polymorphism acts as an intragenic modifier of mutant p53 behaviour , 2000, Nature Genetics.

[32]  D. Ryberg,et al.  p53 mutations in defined structural and functional domains are related to poor clinical outcome in non-small cell lung cancer patients. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

[33]  Miranda Thomas,et al.  Two Polymorphic Variants of Wild-Type p53 Differ Biochemically and Biologically , 1999, Molecular and Cellular Biology.

[34]  C. Prives,et al.  p73 Function Is Inhibited by Tumor-Derived p53 Mutants in Mammalian Cells , 1999, Molecular and Cellular Biology.

[35]  L. Bracco,et al.  The requirement for the p53 proline‐rich functional domain for mediation of apoptosis is correlated with specific PIG3 gene transactivation and with transcriptional repression , 1998, The EMBO journal.

[36]  A. Levine,et al.  A comparison of the biological activities of wild‐type and mutant p53 , 1993, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[37]  U. Pastorino,et al.  Deletions of 17p and p53 mutations in preneoplastic lesions of the lung. , 1992, Cancer research.

[38]  J. Minna,et al.  p53: a frequent target for genetic abnormalities in lung cancer. , 1989, Science.

[39]  D. Pim,et al.  Primary structure polymorphism at amino acid residue 72 of human p53 , 1987, Molecular and cellular biology.

[40]  C. Harris,et al.  p53: traffic cop at the crossroads of DNA repair and recombination , 2005, Nature Reviews Molecular Cell Biology.

[41]  J. Levine,et al.  Surfing the p53 network , 2000, Nature.

[42]  C. Harris,et al.  Molecular epidemiology of human cancer: contribution of mutation spectra studies of tumor suppressor genes. , 1998, Cancer research.